What is Progenesis?
Founded in 2015 and headquartered in La Jolla, California, Progenesis operates as a high-authority provider of preimplantation genetic testing (PGT). The company distinguishes itself through a comprehensive suite of diagnostic services, including Previda for PGT-A and Previda-DX for PGT-M/SR, alongside mitochondrial DNA assessments via MitoSure. By integrating advanced genomic analysis with the Revela online portal for genetic counseling, Progenesis bridges the gap between complex laboratory diagnostics and patient-facing reproductive support. Their market position is defined by a commitment to precision medicine, serving as a critical partner for fertility clinics and couples navigating the complexities of IVF treatments.
How much funding has Progenesis raised?
Progenesis has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Progenesis
PPP
Public-Private Partnership
What's next for Progenesis?
With this latest round of backing, Progenesis is positioned to accelerate its technological roadmap and expand its footprint in the global fertility market. The strategic allocation of this capital will likely focus on enhancing the throughput of their genetic testing platforms and broadening the reach of their digital counseling services. As the demand for sophisticated reproductive health diagnostics continues to rise, Progenesis is well-equipped to leverage its existing infrastructure to capture additional market share. Future growth trajectories will likely involve deepening clinical partnerships and refining their proprietary diagnostic algorithms to maintain a competitive edge in the rapidly evolving field of reproductive genetics.
See full Progenesis company page
